BREAKING NEWS
Search
yahoo

Traders Buzz: Amgen Inc. (NASDAQ:AMGN), Novavax, Inc. (NASDAQ:NVAX), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Amgen Inc. (NASDAQ:AMGN)’s shares declined 0.66% to $118.98. The company on July 1 announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE®) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow. The Breakthrough Therapy Designation was based on the results of a Phase 2 trial of 189 adult patients with Ph- relapsed/refractory B-precursor ALL treated with blinatumomab.

Get the Inside Scoop On AMGN here with this Free Report

Novavax, Inc. (NASDAQ:NVAX)’s shares droped 1.75% to $4.49. The company on June 23 announce that it has been recognized as one of The Washington Post Top Workplaces. The Washington Post Top Workplaces are determined based solely on employee feedback. The employee survey was conducted by WorkplaceDynamics, LLP, a leading research firm on organizational health and employee engagement. Over the past year, more than 5,000 organizations in the U.S. have turned to WorkplaceDynamics to better understand what’s on the minds of their employees. Through its workplace improvement offerings, WorkplaceDynamics provides solutions, training and tools to help clients improve their workplace.

You won’t believe what we found out about NVAX

Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s shares increased 1.05% to $2.88. The company was scheduled to be added to the Russell 3000 and Russell 2000 Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, 2014, according to a preliminary list of additions posted on June 13, 2014 on www.russell.com/indexes. The company  is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) – and ribonucleic acid (RNA) – based drug candidates.

Why Should You Buy IDRA Now? Get The Free Trend Analysis Here




Chris Hurst joined the Market Buzz Media news staff in June 2010 following a long career in radio. Chris Hurst was News reporter and morning news anchor at KAUS radio in Austin. During that time, KAUS won more than 8 awards for excellence in news coverage from organizations including the Minnesota Associated Press, Minnesota News Network, Iowa Associated Press, Minnesota Emergency Managers Association, Minnesota Education Association and others. Chris Hurst attended the former Austin Community College and Austin Vocational - Technical Institute, both of which are now parts of Riverland Community College. He also writes a weekly column for the Austin edition of the Post Bulletin newspaper. Away from work Chris enjoys astronomy and train watching, hobbies he shares with his five year old son Steven. They can often be found in their driveway at night peering through a telescope, or trackside watching trains go by.